LIMD1 and lung adenocarcinoma: The results of the CCK-8 assay showed that upon SB203580-mediated inhibition of the p38 MAPK signaling pathway, there was no significant difference in the cell growth and viability between the LIMD1 overexpression group and the control group in the presence of cisplatin, indicating that LIMD1 could no longer increase the sensitivity of lung adenocarcinoma cells to cisplatin.